Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

554
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
554
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

352
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
352
Bioavailability: Influencing Factors01:22

Bioavailability: Influencing Factors

590
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
590
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

327
Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
327
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

72
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
72
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

208
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
208

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Are electronic health record big data ready for secondary use in research? Exploring potential limitations with opioids as a case study.

Health informatics journal·2025
Same author

Identifying Medication Review Topics to Be Documented in a Structured Form in Electronic Health Record Systems: Delphi Consensus Survey.

Journal of medical Internet research·2025
Same author

Developing a medication-safety self-assessment tool for rural primary care units - a case from Finnish Lapland.

BMC primary care·2025
Same author

Engaging Community Pharmacies in Promoting Outpatient Medication Safety - Identifying and Prioritizing Research Needs by Modified Nominal Group Technique.

Risk management and healthcare policy·2025
Same author

Medication Errors and Error Chains Involving High-Alert Medications in a Paediatric Hospital Setting: A Qualitative Analysis of Self-Reported Medication Safety Incidents.

Drugs - real world outcomes·2024
Same author

Drawing up the public national Rational Pharmacotherapy Action Plan as part of social and health services reform in Finland: a bottom-up approach involving stakeholders.

BMC health services research·2024

Related Experiment Video

Updated: Apr 5, 2026

Real-time Cytotoxicity Assays in Human Whole Blood
08:27

Real-time Cytotoxicity Assays in Human Whole Blood

Published on: November 7, 2014

12.8K

Financial Toxicity Associated with Biological Medicines: A Scoping Review.

Laura Sara Maria Saarukka1, Kamilla Yamileva2, Kari Linden2,3

  • 1Faculty of Social Sciences, University of Helsinki, Helsinki, Finland.

Clinical Pharmacology and Therapeutics
|April 3, 2026
PubMed
Summary

Financial toxicity, the economic burden from healthcare costs, significantly impacts patients on biological medicines. High out-of-pocket expenses and insurance barriers are key drivers, necessitating better patient support systems.

More Related Videos

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

4.6K
Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

5.9K

Related Experiment Videos

Last Updated: Apr 5, 2026

Real-time Cytotoxicity Assays in Human Whole Blood
08:27

Real-time Cytotoxicity Assays in Human Whole Blood

Published on: November 7, 2014

12.8K
Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

4.6K
Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

5.9K

Area of Science:

  • Health Economics
  • Pharmacoeconomics
  • Patient Advocacy

Background:

  • Financial toxicity, encompassing economic burden and its consequences, is a critical issue for patients undergoing biological therapies.
  • High medication and healthcare costs create substantial material, psychosocial, and behavioral challenges for patients.
  • Understanding the scope of financial toxicity is crucial for developing effective patient support strategies.

Conclusions:

  • Financial toxicity in biological therapy patients is a complex issue with both economic and psychosocial dimensions.
  • There is an urgent need for integrated support systems addressing the multifaceted challenges faced by these patients.
  • Future research should focus on strategies to enhance treatment accessibility while minimizing the financial burden on patients.